US FDA May Start To Miss User Fee Deadlines

As the COVID-19 response begins to strain agency’s resources, Commissioner Hahn acknowledges that ‘it is possible that we will not be able to sustain our current level of performance indefinitely’ in other review areas.

Overheated Car Engine_745998352_1200.jpg
The US FDA's product review engine is still running despite the strain of COVID-19, but it's starting to overheat.

US FDA Commissioner Stephen Hahn acknowledged in a 16 April statement that the strain the agency is feeling from its coronavirus response could cause it to miss some of its user fee deadlines.

“At this time, the New Drug Program, the Generic Drug Program, and the Biologics and Biosimilars Programs are continuing to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet